Evidence map›Paper›PMID 33731272›Full record

ArticleGynecologic oncology2021

Corrigendum to "Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations" [Gynecologic Oncology 156 (2020) 363-376].

Ian Solsky, Jinbo Chen, Timothy R Rebbeck

Abstract readPublished Erratum
In one paragraph

Article in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ian SolskyHarvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Jinbo ChenUniversity of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Timothy R RebbeckHarvard T.H. Chan School of Public Health, Boston, MA, United States of America; Dana Farber Cancer Institute, Boston, MA, United States of America. Electronic address: Timothy_Rebbeck@dfci.harvard.edu.

Funding

Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
Modifiers of Cancer Risk in BRCA 1/2 Mutation CarriersR01CA102776 · NCI · UNIVERSITY OF PENNSYLVANIA · PI REBBECK, TIMOTHY R · 2004 to 2008
$3.0M
NCI NIH HHS P20 CA233255NCI NIH HHS R01 CA102776
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33731272
PMCPMC9162145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.